AstraZeneca PLC (AZN)vsFortress Biotech Inc Pref Series A (FBIOP)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
FBIOP
Fortress Biotech Inc Pref Series A
$20.43
-0.24%
HEALTHCARE · Cap: $77.81M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 95438% more annual revenue ($60.44B vs $63.26M). AZN leads profitability with a 17.2% profit margin vs 10.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
FBIOP
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+13.2%
Fair Value
$13.03
Current Price
$20.43
$7.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Every $100 of equity generates 79 in profit
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Trading at 12.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : FBIOP
The strongest argument for FBIOP centers on Return on Equity.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : FBIOP
The primary concerns for FBIOP are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while FBIOP is a value play — different risk/reward profiles.
FBIOP carries more volatility with a beta of 1.16 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 28/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Fortress Biotech Inc Pref Series A
HEALTHCARE · BIOTECHNOLOGY · USA
Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotech products. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?